What are the Challenges Associated with Efflux Pump Inhibitors?
Despite their potential, the clinical application of EPIs faces several challenges:
- Toxicity: Many EPIs are not selective and can inhibit efflux pumps in normal tissues, leading to adverse effects. - Pharmacokinetics: EPIs can alter the pharmacokinetics of co-administered drugs, making dose optimization challenging. - Drug Interactions: The use of EPIs can lead to significant drug-drug interactions, complicating treatment regimens. - Resistance: Cancer cells can develop resistance mechanisms against EPIs themselves, limiting their long-term efficacy.
